Cooperative Agreement U01CA313445
Award Date 8/7/26
Completion Date 7/31/31
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...
- The National Cancer Institute awarded The Leland Stanford Junior University $550,897 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of tolerogenic macrophages in tumor metastasis, with particular focus on hepatic metastatic spread. The research examines how tumors educate local macrophages expressing the erythropoietin receptor (EPOR) to adopt an immunoregulatory phenotype through EPO signaling, creating a non-inflamed tumor microenvironment...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded $694,015 to the Beckman Research Institute of the City of Hope on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and target cancer immune evasion signals against macrophage surveillance. The research investigates mechanisms by which cancer cells evade immune detection, with focus on tumor-associated macrophages and their capacity to recognize and eliminate cancer cells through programmed cell removal. The project...
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute of the Department of Health and Human Services awarded the Beckman Research Institute of the City of Hope $733,864 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints regulating macrophage-mediated programmed cell removal in tumor immunosurveillance. The research uses high-throughput CRISPR-based screening to investigate how a novel stimulatory innate immune checkpoint interacts with...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded a cooperative agreement totaling $681,310 to The Trustees of Columbia University in the City of New York on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The funded research investigates mechanisms that promote bone metastasis in prostate cancer, the major cause of death in metastatic prostate cancer patients. Columbia will use genetically-engineered mouse models (GEMMs) to...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...